India to recalibrate air quality standards next year

NEW DELHI: India is likely to have new national ambient air quality standards (NAAQS) in 2022, factoring in more pollutants, including ultra-fine particulate matter of less than PM2.5. The existing national standard was formulated 12 years ago.

The Central Pollution Control Board (CPCB) has already awarded the work of updating NAAQS to the IIT Kanpur-led team of experts, including scientists from IIT Delhi, National Physical Laboratory (NPL), NEERI and AIIMS. The team will recommend the revised standards by fine-tuning and broadening the pollutants’ base.

“A Memorandum of Understanding (MoU) will soon be signed between CPCB and IIT-Kanpur. The team will be given 12 months to finalise its report,” said an official in the environment ministry.

India’s first NAAQS was adopted in 1982 and subsequently revised in 1994 and 2009, factoring in eight pollutants— particulate matters (PM2.5 and PM10), sulphur dioxide, nitrogen dioxide, carbon monoxide, benzene, ammonia and ozone.

The expert group will examine the criteria adopted by different countries and WHO’s guidelines before arriving at its final suggestions. The scientists will also factor in India’s geographical position and meteorological conditions while recommending updates for the NAAQS.

“The group will submit its recommendations to CPCB which, in turn, will give its final go-ahead to it after considering views of stakeholders through public consultations,” said the official.

Besides expanding the scope of measurements for different pollutants by redefining areas, time period for long and short-term values and frequency of measurements, the group will also analyse effects of air pollutants on human health and vegetation.

The ‘scope of work’ for the group, accessed by TOI, shows that the team will conduct primary health surveys at multiple locations, where high concentrations of various pollutants are reported, for establishing the “health effects of various pollutants”. The locations for this survey will be decided in consultation with CPCB.

Suggestions on guidelines for designing of monitoring network, setting up of monitoring locations, data validation protocol, review of ‘air quality index’ (AQI) and use of various technologies for monitoring are also part of the ‘scope of work’ for the expert group.

  • Related Posts

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’